Key Takeaways
- The Federal Reserve has cut interest rates by 0.5%, the first cut since 2020, which has investors feeling hopeful for the biopharma sector. The XBI is also up 2.6% from last week.
- A reflection on the obesity market and GLP-1 revolution.
- Lilly’s follow up to the FDA’s ruling that Lilly’s new GLP-1 receptor agonist retatrutide is a peptide and not a biologic. Lilly claim that with their modifications, the sequence is 41 amino acids, but the FDA disagrees.
- A selection of interesting recent publications including:
- Alexander Dityatev’s discussion of Beddows et al. (2024) publication in Nature, describing the role of the ECM in the brain in obesity.
- A review of the global burden of antimicrobial resistance published in Lancet (GBD 2021, 2024).
- Boehringer’s Pan-KRAS inhibitor described in Science. (Popow J. et al., 2024)
- A new Nature Communications paper tying prostate cancer progression to MYC activation (Graham & Wang et al., 2024).